TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00819468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teduglutide
Description: Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
Study: NCT03837873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 750mg/m2 i.v. on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50mg/m2, continuous i.v. on day 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4mg/m2, continuous i.v. on day 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10mg/m2, continuous i.v. on day 1-4
Study: NCT01842282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlexanox
Study: NCT01580202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5mg daily per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100mg daily per os
Study: NCT02630823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection (standard of care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (standard of care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (standard of care)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (standard of care)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Study: NCT00616005

Intervention type: DRUG
Group type: OTHER
Intervention: Temodar and Irinotecan
Description: Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Temodar and Irinotecan
Description: Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
Study: NCT02625597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyvinylsiloxane
Study: NCT01595347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyper-oxigenated fatty acid
Description: Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil's cream
Description: Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
Study: NCT05124132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Mindfulness-Based Stress Reduction
Study: NCT03837873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m2, i.v. on day5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg/day, p.o. on day 0-9
Study: NCT05124132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction + Exercise
Description: Mindfulness-Based Stress Reduction + Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health Education
Study: NCT01179152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler
Description: Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler
Description: Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler
Description: Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
Study: NCT03666221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
Study: NCT03837873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m2 continuous i.v. on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2 q12h, i.v. on day 2
Study: NCT01422863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
Study: NCT00445770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 10 mg twice weekly, subcutaneous injection for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 25 mg, twice weekly, subcutaneous injection for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: up to 8 mg per week, oral dosing for 52 weeks
Study: NCT04932642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT+RT experimental group
Description: Each experimental group will be compared with their another contrast order session group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT+HIIT experimental group
Description: Each experimental group will be compared with their another contrast order session group
Study: NCT02562859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg GLPG1837 as oral suspension
Description: A single dose of 500 mg GLPG1837 administered as oral suspension
Study: NCT01880112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
Study: NCT00828191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 25 mg, once a day, SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 100 mg, twice a day, vaginally
Study: NCT03627819

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterol-enriched margarine
Description: Margarine enriched with plant sterol esters

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant stanol-enriched margarine
Description: Margarine enriched with plant stanol esters
Study: NCT02562859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg GLPG1837 as oral tablet
Description: A single dose of 500 mg GLPG1837 administered as oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg GLPG1837 as oral tablet
Description: A single dose of 500 mg GLPG1837 administered as oral tablet
Study: NCT03627819

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control margarine
Description: Margarine without any addition
Study: NCT01065519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V everolimus eluting stent
Description: Xience V everolimus eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus A9-eluting Biomatrix stent
Description: Biolimus A9-eluting Biomatrix stent
Study: NCT00982475

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary vein isolation with radiofrequency current
Description: Pulmonary vein isolation with radiofrequency current

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation with radiofrequency current
Description: Pulmonary vein isolation with radiofrequency current
Study: NCT00600938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core Study: Deferasirox
Description: 20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
Study: NCT03156374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test use
Description: Use of home ovulation test to predict ovulation
Study: NCT00600938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Core Study: Deferoxamine
Description: 50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
Study: NCT03797456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
Study: NCT00600938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension: deferoxamine to deferasirox
Description: 40 mg/kg deferasirox once daily administered 30 minutes before taking food.
Study: NCT03121703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar stabilization exercise
Description: lumbar stabilization exercise

Intervention type: OTHER
Group type: OTHER
Intervention: trunk muscle strengthening exercise
Description: trunk muscle strengthening exercise
Study: NCT01704404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Study: NCT00600938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension: deferasirox to deferoxamine
Description: DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Study: NCT00714519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenaderm® Ointment
Description: Topical, BID or as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Topical, BID or as needed
Study: NCT01727076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interleukin-15
Description: Given SC
Study: NCT01219400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin (50 mg BID) given for four weeks
Study: NCT01704404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Study: NCT02862288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation with Acculis Accu2i pMTA Applicator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation with Acculis Accu2i pMTA Applicator
Study: NCT01704404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03872791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
Study: NCT04204044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin Hydrochloride is used in PCO
Study: NCT02741908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie counting diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed diet plan
Study: NCT02642432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT01048021

Intervention type: PROCEDURE
Intervention: Supraclavicular Block
Description: Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position.
Study: NCT02862288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation with Acculis Accu2i pMTA Applicator
Study: NCT03907488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo peripheral blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo peripheral blood collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study: NCT01806896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: * Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Treatment for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: - Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: * 5mg dose~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days.
Study: NCT01806896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days.
Study: NCT00004078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT00316199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2, intravenous (IV), every 21 days until disease progression
Study: NCT00593671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation genetic screening after embryo biopsy
Description: Preimplantation genetic screening after embryo biopsy
Study: NCT02081690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan tablet, dose of 10 mg, once daily
Study: NCT00959842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: 1 gram gel capsule 4 capsules per day for 8 weeks
Study: NCT03645655

Intervention type: DIAGNOSTIC_TEST
Intervention: PIVKA-II
Description: Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
Study: NCT00564447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin topical solution 1% given as a single drop in a single eye
Study: NCT04204044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo inositol used in PCO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo inositol used in PCO
Study: NCT02497911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Catheter
Description: 0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular Catheter
Description: 0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Study: NCT01566955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transgastric adnexectomy
Description: adnexectomy transgastrically with transvaginal support
Study: NCT04372680

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTUS examination
Description: fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
Study: NCT01832025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: internal maxillary sinus floor elevation technique
Description: The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external maxillary sinus floor elevation technique
Description: The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
Study: NCT04221685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artpharma
Description: ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artinibsa
Description: Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
Study: NCT03510286

Intervention type: DIAGNOSTIC_TEST
Intervention: Test-it™ PrCr Urinalysis Strips
Description: The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
Study: NCT00531232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Pharmaceutical form: Tablet,~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Pharmaceutical form: Tablet,~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Pharmaceutical form: Tablet,~Route of administration: Oral